Cocrystal Pharma (COCP) Total Non-Current Liabilities (2011 - 2026)

Cocrystal Pharma (COCP) has 13 years of Total Non-Current Liabilities data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 24.09% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (down 24.09% YoY), and the FY2025 full-year result was $1.2 million, down 22.19% from the prior year.
• Total Non-Current Liabilities eased to $1.1 million in Q1 2026, from $1.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.6 million in Q4 2023 to a low of $27000.0 in Q1 2023.
• A 5-year average of $912307.7 and a median of $1.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities sank 88.46% in 2023 and surged 5759.26% in 2024, its largest moves.
• Tracing COCP's Total Non-Current Liabilities over 5 years: stood at $57000.0 in 2022, then soared by 2729.82% to $1.6 million in 2023, then slipped by 6.7% to $1.5 million in 2024, then declined by 22.19% to $1.2 million in 2025, then dropped by 7.69% to $1.1 million in 2026.
• Business Quant data shows COCP's Total Non-Current Liabilities at $1.1 million in Q1 2026, $1.2 million in Q4 2025, and $1.3 million in Q2 2025.